Humacyte Regains Global Rights to Symvess Vascular Graft

Humacyte ( (HUMA) ) has provided an announcement.

On April 21, 2026, Humacyte entered a third amendment to its distribution agreement with Fresenius Medical Care, regaining sole global rights to develop, commercialize and manage regulatory matters for its 6mm Symvess acellular tissue engineered vessel. In exchange for the reversion of ex-U.S. rights, Humacyte will pay Fresenius low-single-digit royalties on net sales outside the U.S. after a two-year royalty-free period in each country, while existing U.S. royalty terms, ranging from mid-single digits to low double digits, remain in place.

Humacyte announced the amended arrangement on April 24, 2026, emphasizing that the realignment of ex-U.S. rights strengthens its ability to pursue international expansion and indication-specific partnerships for Symvess, including previously announced commercial initiatives in Saudi Arabia and Israel. Fresenius, the company’s long-time partner and largest shareholder, remains obligated to adopt Symvess as a standard of care in eligible hemodialysis patients where supported by clinical and health economic data, preserving a key commercial channel as Humacyte seeks to scale its bioengineered vascular products globally.

The most recent analyst rating on (HUMA) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.

Spark’s Take on HUMA Stock

According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.

The score is primarily constrained by weak financial performance (minimal/declining revenue, large losses, heavy cash burn, and high leverage). Technicals also indicate a downtrend with bearish momentum, despite oversold conditions. Offsetting these, the earnings call conveyed improving early commercial traction for Symvess, positive clinical data, and extended runway from recent financing, but these positives are not yet large enough to outweigh the current financial and trend risks.

To see Spark’s full report on HUMA stock, click here.

More about Humacyte

Humacyte, Inc. is a commercial-stage biotechnology platform company that develops universally implantable, bioengineered human tissues designed to treat a wide range of diseases, injuries and chronic conditions. Its lead products are acellular tissue engineered vessels (ATEVs), including Symvess, which received U.S. FDA approval in December 2024 for extremity vascular trauma and is in late-stage trials for hemodialysis arteriovenous access and peripheral artery disease.

The company is also advancing preclinical programs in coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes and other novel cell and tissue applications. Several of Humacyte’s 6mm ATEVs hold FDA Regenerative Medicine Advanced Therapy and Fast Track designations, and the vascular trauma indication has priority designation from the U.S. Secretary of Defense, underscoring the platform’s strategic and clinical significance.

Average Trading Volume: 6,742,993

Technical Sentiment Signal: Sell

Current Market Cap: $157.2M

See more data about HUMA stock on TipRanks’ Stock Analysis page.